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Simple Summary: Rational use of antibiotic is of most importance for human and animal health.
Donkeys have differences in metabolism compared to horses, and drug dosage should not be
extrapolated from horses’ data. Doxycycline, a common antibiotic used in equine medicine, has never
been investigated in donkeys. The aim of this preliminary study was to describe the concentrations
of doxycycline obtain in serum and other body tissue and fluid following its oral administration in
donkeys at the recommended horse dosage. Doxycycline was administered to eight healthy, adult
jennies. Serum, urine, synovial fluid and uterine tissue were collected. Doxycycline concentrations
were measured with a commercial ELISA. A pharmacological model was used to analyze the serum
concentration and calculate some pharmacological parameters. Results suggest that doxycycline is
well absorbed following oral administration and calculated serum parameters suggest high tissue
distribution. However, the concentration of doxycycline reached in all fluids and tissues analyzed
would unlikely result in therapeutic concentration against common equine pathogens. Further
investigations are warranted. This data can be used for designing future studies of doxycycline in
donkeys. In the meantime, oral doxycycline at the horse dosage should not be consider a suitable
treatment in donkeys until proven efficacious.
Abstract: Doxycycline (DXC) is a broad-spectrum antibacterial antimicrobial administered to horses
for the treatment of bacterial infections which may also affect donkeys. Donkeys have a different
metabolism than horses, leading to differences in the pharmacokinetics of drugs compared to horses.
This study aimed to describe the population pharmacokinetics of DXC in donkeys. Five doses of
DXC hyclate (10 mg/kg) were administered via a nasogastric tube, q12 h, to eight non-fasted, healthy,
adult jennies. Serum, urine, synovial fluid and endometrium were collected for 72 h following the
first administration. Doxycycline concentration was measured by competitive enzyme immunoassay.
Serum concentrations versus time data were fitted simultaneously using the stochastic approximation
expectation-maximization algorithm for nonlinear mixed effects. A one-compartment model with
linear elimination and first-order absorption after intragastric administration, best described the
available pharmacokinetic data. Final parameter estimates indicate that DXC has a high volume of
distribution (108 L/kg) as well as high absorption (10.3 h−1) in donkeys. However, results suggest
that oral DXC at 10 mg/kg q12 h in donkeys would not result in a therapeutic concentration in serum,
urine, synovial fluid or endometrium by comparison to the minimum inhibitory concentration of
common equine pathogens. Further studies are recommended to identify appropriate dosage and
dosing intervals of oral DXC in donkeys.
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1. Introduction
Donkeys (Equus asinus) remain a source of income in the cosmetic, tourism, farming,
and food (milk and meat) industries. Even if the worldwide donkey population is decreas-
ing, donkeys have taken a greater place in society as companion animals, and now are
used for emotional support (asino- or onotherapy), increasing the demand for veterinary
medical management [1]. In recent years, donkey farming has gained popularity in several
countries with a growing interest in milk production [2]. Indeed, consumption of donkeys’
milk is encouraged because of its beneficial human health properties. When compared to
cow’s milk, donkeys’ milk is a better milk replacement option for infants and a suitable
milk source for people suffering from cow’s milk allergies [2,3]. It is important to conduct
pharmacological studies to investigate medical treatment options for donkeys. Further-
ing research in this area will help maintain the welfare of the reared donkeys, as well as
guaranteeing human biosecurity, specifically regarding withdrawal time to apply in food
production. Donkeys are classified as a minor species by the Food and Drug Administration
and no drugs are labeled for use in this species. Therefore, drugs, including antibacterial
antimicrobials, are used in an extra-label manner in donkeys. However, the metabolic rate
and cellular water content are higher in donkeys than in horses. Most antibacterials have a
higher clearance, lower mean residential time and shorter half-life in mules and donkeys.
Higher dosages and/or shorter intervals between dosage are often required in this species
when compared to horses; therefore, dosages should not be directly extrapolated from
horses’ pharmacologic data [4]. These drug metabolism discrepancies present an obvious
need for pharmacologic studies in Equus asinus species to provide evidence-based medical
treatments to these animals, as well as for establishing withdrawal times.
Pharmacologic studies in donkeys of antibacterials include ß-lactams (amoxicillin, ampi-
cillin, penicillin G), aminoglycosides (amikacin, gentamicin), fluoroquinolones (danofloxacin,
enrofloxacin, marbofloxacin, norfloxacin), oxytetracycline, sulfonamides (sulfadimidine, sulfa-
diazine, sulfadimethoxine, sulfamethoxazole, sulfamethoxypyridazine), and trimethoprim [4].
However, even if oral medication is desirable in equine medicine for ease, safety and com-
pliance, the sole oral antibacterial studied in donkeys to date is norfloxacin. Norfloxacin has
demonstrated poor bioavailability and is thus suggested not usable based on the minimum
inhibitory concentration (MIC) reported of common susceptible bacteria in equine [5]. Fur-
thermore, following antimicrobial stewardship principles, pharmacologic studies in veterinary
medicine should focus priorities on lower-ranked critical molecules for human medicine [6],
therefore doxycycline warrants some investigation.
Doxycycline (DXC) is a semi-synthetic analog of tetracycline and has broad-spectrum
co-dependent bacteriostatic properties [7]. The pharmacokinetics of DXC following oral
administration in adult healthy horses have been studied [8–14]. These studies suggested
that oral DXC at 10 mg/kg q12 h reached adequate concentration for the treatment of
susceptible bacteria with a MIC lower than 0.25 µg/mL in serum, peritoneal fluid, synovial
fluid, endometrium, pulmonary epithelial lining fluid, and urine. If administered orally
at 20 mg/kg q12 h, the concentration of DXC reached a concentration of 29 µg/mL in
polymorphonuclear leukocytes [10]. However, multiple horses experienced colic, and
one horse died from fatal colitis. Other side effects reported in horses following oral
administration of DXC include anorexia and photosensitization [10,12].
Some authors suggested the clinical efficacy of oral DXC in horses for the treatment
of intra-abdominal or cutaneous abscesses from Glanders [15,16], neuroborreliosis [17],
granulocytic ehrlichiosis, neorickettsiosis, and leptospirosis [10]. Natural infection of
neorickettsiosis (Potomac horse fever) has not been reported in the donkey but could be
replicated experimentally [18]. Antibodies against Anaplasma phagocytophilum have been
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detected in donkeys [19]. There are no reports of intra-abdominal abscessation in donkeys,
but pathogens that can cause abscessation such as Streptococcus zooepidemicus and S. equi
have been isolated in donkeys [20]. Glanders, neuroborreliosis, leptospirosis have also been
reported in donkeys [21]. Therefore, DXC warrants investigation in donkeys to support its
use for the medical management of these diseases in this species.
This study aimed to investigate the pharmacokinetics of DXC by determining its distri-
bution in serum, urine, synovial fluid, and endometrium after intragastric administrations
of 5 doses of DXC at 10 mg/kg PO, q12 h in healthy jennies.
2. Materials and Methods
The study was approved by the Institutional Animal Care and Use Committee at Ross
University School of Veterinary Medicine (RUSVM), number 16-10-032.
2.1. Animals
Eight healthy adult Caribbean crossbred jennies, from 4 to 12 years old, weighing
between 120 kg and 180 kg (weights rounded to the nearest 10 kg), were randomly selected
from the teaching herd of the RUSVM. Inclusion criteria included normal physical exami-
nation and complete blood counts. All jennies were housed in an outside dry pen and were
fed ad libitum guinea grass and water.
Jennies were monitored during the study until the last sample collection (72 h after
initiation of the medication) and then regularly as part of the teaching herd. All jennies
remained healthy 4 years after the study.
2.2. Experimental Design and Sample Collection
Doxycycline hyclate 100 mg coated tablets (West-Ward Pharmaceuticals Corp., Eaton-
town, NJ, USA) were dissolved in 20 mL of tap water to prepare individual doses of
10 mg/kg. The DXC was administered via a nasogastric tube, which was flushed with
500 mL of tap water prior to removal to ensure complete delivery of the DXC. Each jenny
received 10 mg/kg of the drug at time point 0 and then q12 h for five doses (0, 12, 24, 36,
and 48 h). Jennies were sedated with xylazine hydrochloride (0.7 mg/kg) intravenously as
needed for sample collection.
Blood samples were collected with a 16 G polyurethane intravenous catheter placed
in the jugular vein prior to the first DXC administration (time 0), and 15, 30 min, as well
as 1, 2, 6, 12, 18, 24, 24.5, 28, 30, 36, 36.5, 42, 48, 48.5, 54, 60, and 72 h following the first
administration. The samples were placed in plain glass blood collection tubes (Covidien,
Mansfield, MA, USA), tubes were centrifuged to separate serum (3000 rpm for 15 min),
and serum was stored at −80 ◦C until analyzed.
Urine samples were collected aseptically using a stallion urinary catheter prior to DXC
administration (time 0) and 24, 36, 48, and 60 h following the first administration. The
samples were placed in Eppendorf tubes and stored at −80 ◦C until analyzed.
One mL of synovial fluid sample was collected from the tibiotarsal joints aseptically
by arthrocentesis, alternating between right and left tarsus. Samples were collected prior to
the DXC administration (time 0), and 24, 36, 48, and 60 h following the first administration.
The samples were placed in glass blood collection tubes, centrifuged (3000 rpm for 15 min)
and supernatant placed in Eppendorf tubes and stored at −80 ◦C until analyzed.
Endometrial tissue samples were collected by obtaining uterine biopsies using en-
dometrial biopsy forceps. Biopsies were collected 51, 60 and 72 h following the first DXC
administration. The samples were placed in sterile, isotonic saline-filled Eppendorf tubes
and stored at −80 ◦C until analyzed.
All the samples were collected prior to DXC administration when the time of sampling
and administration of DXC were concomitant.
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2.3. Measure of DXC
Total doxycycline was measured by competitive enzyme immunoassay (MaxSignal ®
Doxycycline ELISA Test Kit, #1083, BIOO Scientific Corp, Austin, TX, USA). The manufac-
turer reports the sensitivity of DXC detection in meat/meat products/fish/shrimp/butter
and the specificity of the kit at 1.5 ng/g and 100.0%, respectively. The kit is manufactured
in accordance with the international quality standard ISO 9001:2008. This ELISA kit was
used in previous studies for measuring the release of DXC from nanotube surface-treated
dental implants loaded with DXC [22], and regulatory residue surveillance [23].
The extraction protocol was adapted from the protocol of DXC concentration analysis
in animal tissues as described in the manufacturer manual for meat and meat products
(#1083-01D, V.14.06, 2014). For measuring DXC in serum, urine and synovial fluid, the
following adaptations were performed: 100 µL of the sample was used instead of 1 g, and
the first mixed sample was only shaken and not vortexed.
The endometrium biopsies were first disrupted in a sterile tissue homogenizer to a
fine pulp. One milliliter of phosphate-buffered saline was added, and the homogenate was
mixed and vortexed at high speed for 2–3 min. The homogenate was placed on ice for
5 min and then clarified at 1000 rpm for 5 min with the centrifuge set at 4 ◦C. The resulting
supernatant was subjected to another round of centrifugation. One hundred microliters
of the supernatant were used and processed for DXC analysis as described above for the
fluid samples.
For serum samples, the intra- and interassay coefficients of variation were 18.1% and
13.1%, respectively. For urine samples, the intra- and interassay coefficients of variation
were 19.5% and 15.8%, respectively. For synovial fluid samples, the intra- and interassay
coefficients of variation were 12.4% and 5.2%, respectively. For uterine biopsy samples, the
intra- and interassay coefficients of variation were 8.9% and 8.2%, respectively.
2.4. Pharmacokinetic Analysis in Serum
2.4.1. Non-Linear Mixed Effect Model Building and Evaluation
All serum concentration DXC data from all donkeys were pooled for nonlinear mixed-
effect (NLME) analysis. Doxycycline serum concentration vs. time courses was evaluated
by the stochastic approximation expectation maximization (SAEM) algorithm implemented
in the Monolix Suite 2019R2 (Lixoft). Individual model parameters were determined post
hoc using the full posterior distribution of the mean as previously described [24,25].
The model was evaluated as described for extravascular administration by
Wang et al. [24,25]. Convergence of the SAEM algorithm was evaluated by inspecting
the stability of the fixed and random effect parameters and estimating the log-likelihood
after the exploratory period (after 1000 iterations of SAEM). Standard goodness-of-fit diag-
nostics, including individual predictions versus observations, the distribution of weighed
residuals (IWRES), and normalized prediction distribution centers (NPDE) were used to
assess the performance of the candidate models. Prediction distributions from 500 Monte
Carlo simulations were used to evaluate the ability of the final model to reproduce the
variability in the observed pharmacokinetic data. Bayesian information criteria (BIC) were
used to select between competing structural models. BIC was selected over the Akaike
Information Criterion as it favors data that tends to be parsimonious [24–26].
Additionally, an estimate of apparent systemic clearance (CL/F) was calculated using:
Kel = CL/Vd
where Kel is the linear elimination rate; V represents the apparent volume of distribution
during the terminal phase after non-intravenous administration (Vz/F), and CL (CL/F)
representing the clearance for extravascular drug administration.
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2.4.2. Estimation of Parameter Correlation
Parameter correlation was estimated as previously described [24,25]. Plots were vi-
sually inspected, and results from the Pearson’s correlation tests were used to inform
our choice of correlations between model parameters. In agreement with previous litera-
ture [27,28], multiple samples from the last SAEM (posterior distribution) obtained at the
last iteration of the SAEM were used during the evaluation of parameter correlations. The
final inclusion of correlations in the structural model was determined by the precision of
the parameter estimates.
3. Results
Eleven of the 160 analyzed serum samples, 2 of the 40 analyzed urine samples, and
1 of the 40 synovial fluid samples were eliminated due to sampling errors. None of the
jennies exhibited side effects.
3.1. Serum
3.1.1. Pharmacokinetic Model Evaluation
A one-compartment model with linear elimination and first-order absorption after
intragastric administration, best described the available pharmacokinetic data based on
standard goodness of fit plots (Figure 1), as well as BIC (Figures 2 and 3).
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Figure 3. Individual predictions of final doxycycline equivalent serum concentrations in donkeys from the final selected
model (n = 8). Scatter plot of observed (blue dot) and predicted (dashed purple line) individual concentration vs. time after
dosing following the fifth intragastric dministration of doxycycline at 10 mg/kg q12 h in 8 healthy jennies.
The predictive performances and robustness of fit of the final model were supported
by the goodness of fit plot inspection, displayed on a log-scale (Figure 1) to better evaluate
the quality of fit as described by Nguyen e al. [29]. In this model of absorption, the 1st
order absorption rate was re resente by Ka.
3.1.2. Estimation of Parameters and Model Evaluation
Tables 1 and 2 provides final estimates of parameters. The precision of the final esti-
mates was high (relative standard error (RSE) ≤ 15%) for Kel, satisfactory for V, (RSE ≤ 25%)
and lower for Ka (RSE ≤ 50%) (Table S1). This model could reproduce the variability
amongst individuals with little individual error (Figures 2 and 3). Of note is the presence
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of inter-individual variability of one jenny (#1, Figures 2 and 3) compared to the other
subjects. The total clearance (CL/F) was estimated to be 2.73 L/kg/hr.
The mean peak concentration of DXC (Cmax) measured in the serum was
0.19 ± 0.13 µg/mL (median 0.13 [0.09–0.26] µg/mL) and 0.21 ± 0.21 µg/mL (median
0.11 [0.09–0.24] µg/mL), following the first and the last doses respectively (Figure 4).
The maximum mean DXC concentration in the serum was 0.27 ± 0.25 µg/mL (median
0.13 [0.09–0.49] µg/mL), measured at 18 h, between the second and third doses.
Table 1. Estimated population model parameters for serum doxycycline concentration after intragas-
tric administration of doxycycline at 10 mg/kg q12 h from 0 to 48 h in 8 healthy jennies.
Parameters Unit Point Estimate Relative Standard Error %
Ka pop. h−1 10.3 45.3
Vz/F pop. L/kg 108 24.4
Kel pop. h−1 0.0253 9.82
Ka, absorption rate constant first order; Vz/F, apparent volume of distribution during terminal phase after
non-intravenous administration; Kel, elimination rate constant from the central compartment.
Table 2. Individual for serum doxycycline concentration after intragastric administration of doxycy-
cline at 10 mg/kg q12 h from 0 to 48 h in 8 healthy jennies.
Parameters Minimum Quartile Q1 Median Quartile Q3 Maximum
Ka 0.102 1.89 20.4 60 171
Vz/F 20.9 62.5 115 204 311
Kel 0.0253 0.0253 0.0253 0.0253 0.0253
Ka, absorption rate constant first order; Vz/F, apparent volume of distribution during terminal phase after
non-intravenous administration; Kel, elimination rate constant from the central compartment.
3.2. Urine
Figure 5 depicts the individual concentration of DXC in urine. The maximum mean
DXC concentration in the urine was 0.13 ± 0.02 µg/mL (median 0.13 [0.12–0.14] µg/mL),
measured at 48 h. The mean concentration in urine was noted to be lower than in serum
for all measurement time points (Figure 4).
3.3. Synovial Fluid
Figures 4 and 6 depict the individual concentration of DXC in synovial fluid. The
maximum mean DXC concentration in the synovial fluid was 0.06 ± 0.03 µg/mL (median
0.07 [0.02–0.09] µg/mL), measured at 48 h. The mean concentration of DXC in synovial
fluid was noted to be lower than in serum for all measurement time points (Figure 4).
3.4. Endometrium
Figures 4 and 7 depict the total DXC measured in endometrium biopsy.
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4. Discussion
In the present preliminary study, serum pharmacokinetic data from repeated intra-
gastric dosing of DXC at 10 mg/kg q12 h in donkeys was reported using the NLME
modeling. Additionally, concentrations of DXC in synovial fluid, urine, and uterine tissue
were reported. To the authors’ knowledge, this is the first study describing oral DXC
pharmacokinetics in donkeys.
Due to the sparse numbers of measurements of serum DXC concentration, the NLME
model approach to estimate pharmacokinetic parameters is recommended [30]. To use a
statistical moment (i.e., non-compartmental) approach, future extravascular pharmacoki-
netic studies should include more intense sampling, especially during the absorption phase,
prior to reaching maximal concentration, as the estimated absorption can be influenced by
the sample collection schedule.
The data was best described by a one-compartment model with linear elimination
after first-order absorption from repeated oral administration. Parameters from the final
model suggest a high volume of distribution (Vz/F, 108 L/kg) and absorption (Ka, 10.3 h−1)
of DXC in donkeys, but a low elimination rate (Kel, 0.0253 h−1). There is a paucity of
information about the volume of distribution (Vd) of DXC in horses [31]. However, DXC
is an extremely lipophilic molecule, and partitioning i the extravascular space should
result in high Vd. The high Vz/F calculated in the present study can explain the low
serum concentration. However, as Vz/F is calculated from serum co centration, it is also
possible that Vz/F was artificially elev t fr the serum values and the Vd would be
lower. Other parameters, such as high cl arance, can cause low serum concentration of
DXC, and Vz/F can be different from the real Vd. Clearance of DXC was estimated at
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2.73 L/kg/h in the current study, whereas the previous study reported a lower value of
42.5 mL/kg/h (0.0425 L/kg/h) in healthy horses [9]. The elimination rate (Kel) in the
present study was estimated from the slope in the elimination phase. Estimated Kel is
lower (0.0253 h−1) than the ones reported in healthy horses ranging from 0.05 ± 0.04
to 0.2 ± 0.0 h−1 [10–12,14]. This suggests that DXC has a longer half-life in donkeys
than in horses. However, the finding of a higher clearance contradicts the findings of
longer half-life and lower elimination rate compared to horses and would require further
investigations. Previous studies reported higher clearance, lower mean residential time and
shorter half-life of most antibacterials in donkeys compared to horses; however, because
exceptions exist, the pharmacokinetics of each antibacterial should be investigated in
donkeys prior to reporting conclusions [4,32].
Urine DXC concentration seems lower in donkeys than in horses following the same
dosage regimen [9]. Therefore, renal excretion of DXC might be lower in donkeys than in
horses. Fecal excretion following hepatic metabolism is the main route of DXC excretion [9]
and should be studied in donkeys. As donkeys have higher metabolic rates than horses [4],
the low serum concentration of DXC and high clearance might be due to a higher hepatic
metabolism in donkeys compared to horses. Nevertheless, future studies should investigate
the concentration of DXC in other tissues to confirm a high Vd, investigate the route and
the metabolic rate of elimination of DXC, and be prepared for a high Vd of DXC in donkeys
to design the sampling methods accordingly. Half-life is a composite of clearance and
Vd. As such, the half-life appears longer in the current study; and as the clearance is
higher than in horses, it can be hypothesized that the longer half-life is related to a larger
Vd in donkeys. In vitro investigations could also be carried out to study donkeys’ organ
metabolism functions as done in horses [33].
Serum concentrations measured were low in the studied population compared to
horses. The maximum mean serum concentration of the jennies was 0.28 ± 0.25 µg/mL
following multiple doses at 18 h, whereas values from 0.32 ± 0.16 µg/mL (following a
single dose) to 0.82 ± 0.13 µg/mL (following multiple doses) were reported in horses [9,11].
Interestingly, 2 of the 8 jennies presented two serum DXC peaks following the first ad-
ministration (#1 and #8, Figure 2). Two peaks following oral DXC administration have
been documented in some healthy horses [8,10], and in infected horses [34]. Some of these
horses were fasted prior to DXC administration, therefore the interaction between DXC and
food might not explain this phenomenon. It is hypothesized this can be from enterohepatic
recirculation of DXC.
Despite a high Vz/F, the measured concentrations of DXC in urine, synovial fluid,
and endometrium were low, this could support the hypothesis of a lower Vd than Vz/F. In
the present study, the mean urine DXC concentration was lower than the mean serum DXC
concentration, whereas it reached 200 to 300 times the mean serum Cmax in healthy horses
medicated with oral DXC at the same dosage regimen [9]. This suggests a lower renal
clearance of DXC in donkeys compared to horses. However, higher metabolism, intestinal
clearance, or Vd could also lower the concentration of DXC in urine. In the present study,
the mean concentrations of DXC in synovial fluid were lower than in the serum, which
suggests that accumulation of DXC in synovial fluid may not occur in the donkey, as it does
in healthy horses [9,12]. In healthy horses receiving the same dosage regimen of DXC, the
mean endometrial DXC concentration was 1.3 ± 0.36 µg/mg, which was 3.6 times the mean
serum DXC concentration 3h after the last administration [9]. In the current study, because
endometrium biopsies were not weighed, the endometrial concentration of DXC could not
be reported. However, it seems unlikely that similar concentrations as to those in horses
would be reached, because 3h after last administration, mean DXC measured in biopsies
was only 0.13 ± 0.06 µg. Because calculated absorption (Ka) and Vz/F were high, but the
measured concentrations of DXC in tissue and body fluids were low in the present study, it
is hypothesized that the metabolism of DXC is different in donkeys than in horses. These
results may be due to the higher metabolic rates and cellular water content in this species
compared to horses [4]. This is consistent with previous findings of higher clearance, lower
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mean residential time and shorter half-life of most antibacterials in donkeys compared to
horses [4].
The calculated absorption of DXC in donkeys in the present study was high (10.3 h−1),
but bioavailability cannot be calculated with the data from this investigation. The deter-
mination of oral DXC bioavailability requires IV administration of DXC to compare the
area under the curve of serum DXC concentration between oral and IV administration.
Intravenous DXC administration results in cardiovascular toxicosis in horses and ponies,
with potentially lethal outcomes [35], at dosages as low as 3 mg/kg [13]. At 10 mg/kg,
intragastric DXC administration to non-fasted horses had a bioavailability of 17%. In top
dressing pellet, oral ingestion of DXC had a bioavailability of 6% [13]. In another study,
bioavailability following intragastric DXC administration at 20 mg/kg to fasted horses was
estimated at 2.7% by allometric analysis [10]. However, an allometric analysis might not be
a suitable technique to estimate the bioavailability of DXC in equids, as it extrapolates data
from other species [36]. Therefore, the intestinal absorption of DXC in donkeys reported in
the present study can be underestimated from concurrent high tissue distribution.
In the present study, DXC mixed in water was administered through a nasogastric
tube, as is done in most pharmacokinetic studies in horses [9–13]. This is not a practical
method of drug administration to all ill animals. The PK of DXC mixed in water and
administered through oral dosing syringes has been investigated in horses [14]. Following
a single administration of DXC mixed with water at 10 mg/kg and administered with oral
syringes to healthy horses, the serum concentrations were comparable to those reported
following intragastric administration [9]. This method of administration should therefore
be investigated in donkeys.
To the authors’ knowledge, there is no report of the common bacterial isolates in
donkeys and their MIC. In equine, bacterial pathogens are reported to be susceptible to DXC
with an in vitro MIC lower than 0.25 µg/mL including all coagulase-positive, β-lactamase
producing staphylococci, some Rhodococcus equi, Streptococcus equi sbsp. equi, S. dysgalactiae
sbsp. equisimilis, some S. zooepidemicus, Acinetobacter spp., most Pasteurella spp., some
Actinobacillus equuli and Taylorella equigenitalis [9,37]. S. zooepidemicus was the primary
isolated pathogen in horses [38] and donkeys seemed highly susceptible to secondary
infection of this opportunistic bacteria [39]. Doxycycline is described as a co-dependent
bacteriostatic antibacterial [7], for which both time-dependent (T > MIC) and concentration-
dependent (Cmax/MIC, AUC/MIC) indices have been reported predictive for clinical
efficacy [40,41]. However, these pharmacokinetic/pharmacodynamic (PK/PD) indices are
specific for combinations of pathogens and species. To the authors’ knowledge, no report
of such indices has been published in the equine species. In addition, it is recognized that
only unbound or free drug is biologically active [42,43]. However, the binding-unbinding
protein phenomenon is a dynamic system; protein-bound drugs can dissociate when the
protein-unbound drug is removed from the system, such as cell penetration. Therefore,
controversies exist regarding the prediction of biological activity of measured unbound-
fraction of the antibiotic [44]. To the authors’ knowledge, no PK/PD studies are reporting
the prediction of biological activity of protein-unbound DXC in equine species. In the
current study, all DXC (protein bound and unbound) was measured. A study reported DXC
to be 82% protein-bound in equine plasma [10]. Therefore, in the current study, the reported
values of DXC serum concentration may overestimate the concentration of biological active
DXC. Overall, considering the MIC of the main isolated equine bacteria [9,37], and based
on the present preliminary findings, oral DXC at 10 mg/kg q12 h seems unlikely to be a
suitable dosage option for the treatment of infectious disease in donkeys. However, PK/PD
integration model studies should investigate the optimal oral DXC dosages for donkeys
for the treatment of specific bacterial isolates in this species [42,45].
Analysis of DXC was not performed by liquid chromatography-mass spectrometry
(LC-MS) or HPLC because of unavailability at the host institution. While ELISA can be a
less sensitive analytical method compared to LC-MS, several studies have shown there are
no significant differences in sensitivity between LC and ELISA kits for some veterinary
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drugs such as flunixin, ractopamine, and chloramphenicol [46–49]. Studies in minor species
are often financially limited, and some in-house laboratories may not be able to invest
in additional equipment. Economical and less labor-intensive techniques such as ELISA
could allow pharmacological studies to be carried out without the need to invest in more
expensive equipment such as that required for LC-MS/HPLC. Therefore, further studies
comparing the sensitivity of analytical methods such as ELISA, LC-MS and/or HPLC
should be pursued.
In the current study, the serum concentrations were low, but no measured values were
below the limit of quantification for the ELISA assay. This suggests the sensitivity could
still be high for this method of analysis. When terminal samples are not below the limit
of quantification, several pharmacokinetic parameters, such as terminal half-life, the Vd,
and mean residence time can be increased as an artifact of assay sensitivity [50]. Overall,
validation of the ELISA kit for measuring DXC in donkey tissues in comparison to LC-MS
is warranted for future studies planning to use this analytical technique.
5. Conclusions
This preliminary study reports pharmacokinetics parameters of DXC following oral
administration in donkeys at 10 mg/kg q12 h and does not support this dosage regimen as a
suitable treatment in donkeys until proven efficacious. This report can be used for designing
future studies of DXC in donkeys. Authors recommend (1) validating the analytical method
of the ELISA kit used, (2) sampling tissues and body fluids more frequently to use a more
conventional pharmacological analysis (such as non-compartmental method), (3) sampling
additional tissues to investigate the Vd, and (4) investigating the route of elimination
of DXC in donkeys, and the main pathogens affecting donkeys and their antibacterial
susceptibilities.
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